Menu
Back to User profile » Dr Donald P Tashkin
Papers published by Dr Donald P Tashkin:
Chronic Obstructive Pulmonary Disease is Not Associated with In-Hospital Mortality in COVID-19: An Observational Cohort Analysis
Toppen W, Yan P, Markovic D, Shover CM, Buhr RG, Fulcher JA, Tashkin DP, Barjaktarevic I
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3111-3121
Published Date: 19 December 2022
Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
Tashkin DP, Ozol-Godfrey A, Sharma S, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:945-955
Published Date: 12 April 2021
Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
Tashkin DP
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3105-3122
Published Date: 27 November 2020
Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy
Tashkin DP, Amin AN, Kerwin EM
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1225-1243
Published Date: 2 June 2020
Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis [Corrigendum]
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine III R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:901-902
Published Date: 23 April 2020
Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Paine III R, Bhatt SP, Bhakta NR, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel N, Wells JM, Ortega VE, Hoffman EA, Doerschuk CM, Kim V, Dransfield MT, Drummond MB, Bowler R, Criner G, Christenson SA, Ronish B, Peters SP, Krishnan JA, Tashkin DP, Cooper CB
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2927-2938
Published Date: 20 December 2019
Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
Tashkin DP, Strange C
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2587-2601
Published Date: 27 August 2018
Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
Tashkin DP, Gross NJ
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1873-1888
Published Date: 12 June 2018
Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease
Tashkin DP, Wechsler ME
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:335-349
Published Date: 17 January 2018
A review of nebulized drug delivery in COPD
Tashkin DP
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2585-2596
Published Date: 18 October 2016
Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis
Halpin DMG, Dahl R, Hallmann C, Mueller A, Tashkin D
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:239-259
Published Date: 5 February 2015
Exacerbation frequency and course of COPD
Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:653-661
Published Date: 21 September 2012
Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:57-71
Published Date: 3 February 2012
Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S
International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:269-275
Published Date: 9 May 2011
Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
Donald P Tashkin
International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:41-53
Published Date: 18 February 2010